HER2-PET scan for metastatic breast cancer treatment
Part of Cancer, Skin clinical trials.
This trial uses a special PET scan (HER2-PET) to see if a targeted drug (trastuzumab deruxtecan) works better for your type of metastatic breast cancer. The goal is to match the treatment to how much HER2 protein your tumors show.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman age 18 or older.
- Your breast cancer has spread to other parts of the body (metastatic) or is locally advanced and has gotten worse after at least one chemotherapy, or came back within 6 months of finishing chemotherapy.
- You have at least one tumor that can be biopsied (or a recent biopsy less than 12 months old with no HER2 therapy or radiation to that spot) and another tumor that can be measured for treatment response.
- You are generally well enough to carry out daily activities (WHO performance score 0-2) and expected to live longer than 12 weeks.
- You do not have a previous biopsy showing your cancer is HER2-positive (IHC 3+ or gene amplification) and you are able to safely undergo trastuzumab deruxtecan treatment (no heart, kidney, liver, or bleeding problems).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special imaging scan to see if your cancer has HER2 on its surface, which could help decide if HER2-targeted treatment might work for you. It's for people with metastatic breast cancer or other solid tumors that have spread.
This study tests a new imaging method (18F-HER2 Affibody PET) to find HER2 protein in breast cancer cells. It may help doctors see which patients might benefit from HER2-targeted treatments.
This study tests a new type of PET scan (a specialized imaging test) to see if it can predict whether chemotherapy will work for HER2-positive breast cancer before surgery. The scan uses a radioactive tracer designed to highlight HER2-positive cancer cells, helping doctors personalize your treatment plan.
This early-phase study uses a special PET scan with a drug tagged for imaging to predict how well HER2-targeted treatments will work. It may help doctors choose the most effective therapy for HER2-positive breast cancer.
This trial uses a special PET scan to see if your breast cancer has low levels of a protein called HER2. This could help doctors choose the right treatment for you.
This study tests a new imaging drug called [68Ga]Ga-ABY-025 to see how well it shows HER2-positive tumors in people who are about to start or have just started HER2-targeted cancer therapy. It may help doctors see if the treatment is working.
Hear when a new Breast Cancer Stage IV trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.